financetom
Business
financetom
/
Business
/
Deutsche Bank Now Sees ECB Rate Cuts "Moving Into The Fast Lane"
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Deutsche Bank Now Sees ECB Rate Cuts "Moving Into The Fast Lane"
Oct 3, 2024 1:40 AM

06:50 AM EDT, 09/26/2024 (MT Newswires) -- Deutsche Bank said it's updating its European Central bank rate cuts call.

The bank had been expecting the ECB to follow a gradual normalization of monetary policy with 25bps rate cuts once per quarter until a terminal rate of 2.00%-2.50% is reached around end-2025, in line with Deutsche Bank's view of neutral.

The bank is moving to a faster normalization call, with the ECB reaching the same terminal rate of 2.00%-2.50% six months earlier in mid-2025.

Deutsche Bank estimates this more rapid easing cycle to be achieved with back-to-back 25bps cuts from December, but it doesn't rule out a 50bps cut in December.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ADF Group Reports Higher Profit, Revenue for Fiscal 2024; to Pay Semi-Annual Dividend
ADF Group Reports Higher Profit, Revenue for Fiscal 2024; to Pay Semi-Annual Dividend
Apr 11, 2024
08:57 AM EDT, 04/11/2024 (MT Newswires) -- ADF Group Inc. ( ADFJF ) , which makes steel structures and components for the construction industry on Thursday reported a more than doubling in net income for the fiscal year ended Jan. 31, 2024. Net income rose to $37.6 million, or $1.15 per basic and diluted share, up from near $15 million,...
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Apr 11, 2024
On Wednesday, Vertex Pharmaceuticals Incorporated ( VRTX ) agreed to acquire Alpine Immune Sciences Inc ( ALPN ) for $65 per share or approximately $4.9 billion in cash.  Alpine’s lead molecule, povetacicept (ALPN-303), is a highly potent and effective dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand).  Through Phase 2 development, povetacicept has shown potential best-in-class efficacy in IgA...
Market Chatter: Spotify Technology Developing Editing Tools for Users
Market Chatter: Spotify Technology Developing Editing Tools for Users
Apr 11, 2024
08:58 AM EDT, 04/11/2024 (MT Newswires) -- Spotify Technology ( SPOT ) is developing tools that would allow subscribers to edit songs from their favorite artists, The Wall Street Journal reported Thursday, citing people familiar with the discussions. The new tools the audio-streaming company is considering include a playback feature that would allow users to adjust the speed of a...
Fiverr Board Authorizes $100 Million Stock Repurchase Plan
Fiverr Board Authorizes $100 Million Stock Repurchase Plan
Apr 11, 2024
08:58 AM EDT, 04/11/2024 (MT Newswires) -- Fiverr International ( FVRR ) said Thursday its board authorized on April 1 the repurchase of up to $100 million of the company's ordinary shares. The company's creditors may apply and object regarding the stock buyback plan until May 4, subject to court approval, Fiverr ( FVRR ) added. The share repurchase plan...
Copyright 2023-2026 - www.financetom.com All Rights Reserved